UroGen Pharma announced strong preliminary results from its Phase 3 UTOPIA trial for UGN-103, showing a 77.8% three-month complete response rate for patients with recurrent low-grade intermediate-risk ...
Despite majoring in engineering, a Cranberry Township woman took on a health-related project when applying to graduate school ...
Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed at expanding the U.S. indications of injectable and intravenous versions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback